Overview

A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).
Phase:
Phase 2
Details
Lead Sponsor:
Hadassah Medical Organization